A genome-wide CRISPR/Cas9 screen in oral squamous cell carcinoma has isolated the histone methyltransferase SUV39H2 as a pivotal driver of resistance against oncolytic herpes simplex virus 1 therapy. This discovery opens novel therapeutic targets to enhance efficacy of oncolytic virus treatments in resistant cancers, as reported recently in Cell Death Discovery.